CoChat

The DOI matches its Crossref record; 128 of the 131 references it cites were found in a registry or an index.

Commonality of the IL-4/IL-13 pathway in atopic diseases

Gandhi, Namita A., Pirozzi, Gianluca, Graham, Neil M. H. · 2017 · Expert Review of Clinical Immunology

Abstract

INTRODUCTION: Allergy results from an aberrant Type 2 inflammatory response, triggered by a wide range of environmental antigens (allergens) that lead to various immune responses, culminating in the production of immunoglobulin E (IgE). Two key cytokines, interleukin (IL)-4 and IL-13, are critical to the induction and perpetuation of the Type 2 response, and have been implicated in multiple atopic diseases. Area covered: This review summarizes recent milestone developments that have elucidated components of the pathogenesis of atopic diseases such as atopic dermatitis (AD), asthma, and chronic sinusitis with nasal polyposis (CSwNP). Expert commentary: Several therapeutic agents that selectively target potentiators of the Type 2 pathway have shown efficacy in one or more of these atopic diseases, but few agents have proven to be broadly applicable across all three atopic diseases. Dupilumab, a human monoclonal antibody that simultaneously inhibits signaling of IL-4 and IL-13, has demonstrated significant clinical efficacy in AD, asthma, and CSwNP. The fact that these diseases often occur as comorbidities and respond to the same therapy suggests that there is a common underlying pathogenic pathway, and that IL-4 and IL-13 cytokines are central to regulating the pathogenesis of these atopic diseases.

Overview

Integrity signals

Registry

Crossref · 10.1080/1744666x.2017.1298443

Cites

128 of 128 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Show all 131 references

Research works printed but not linked: 16

  1. Thomsen SF, 2015, Eur Respir J, 2
  2. Normansell R, 2014, Cochrane Database Syst Rev, 1:Cd003559
  3. Chauhan BF, 2014, Cochrane Database Syst Rev, Cd003137
  4. Heil PM, 2010, J Dtsch Dermatol Ges, 8, 990
  5. Powell C, 2015, Cochrane Database Syst Rev, Cd010834
  6. Gascan H, 1991, J Immunol (Baltimore, Md: 1950)
  7. Gauvreau GM, 2010, Am J Respir Crit Care Med
  8. Walsh GM, 2010, Curr Opin Investig Drugs, 11, 1305
  9. Groves RW, 2007, J Invest Dermatol, 127, S54
  10. Wenzel SE, 2010, Inhaled pitrakinra, an IL-4/IL-13 antagonist reduces exacberbations in patients with eosinophilic asthma
  11. 2015, Ist Quarter Res
  12. Simpson E, 2016, Effiacy and safety of lebrikizumab in patients with atopic dermatitis: a Phase 2 randomized, controlled trial (TREBLE)
  13. 2016, Global Strategy for Asthma Management and Prevention (Revised 2016)
  14. Nicola A, 2016, LAVOLTA I and II: design and baseline characteristics of two phase III, randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of lebrikizumab in adult patients with uncontrolled asthma
  15. Gevaert P, 2013, J Allergy Clin Immunol, 131, e1
  16. Pawankar R, 2011, WAO White Book on Allergy World Allergy Organization

Cited by

See all 493

Metadata

Authors
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H.
Affiliations
  • Regeneron (United States) (US)
  • Sanofi (United States) (US)
Corresponding author
Gandhi, Namita A.
Venue
Expert Review of Clinical Immunology
Published
2017-03-15
Volume
13
Issue
5
Pages
425-437
ISSN
  • 1744-666X (ISSN-L)
  • 1744-8409
OpenAlex
W2594033175
Cited by
493
References
131
Citations by year
2026: 39 · 2025: 53 · 2024: 75 · 2023: 72 · 2022: 79 · 2021: 69 · 2020: 40 · 2019: 38 · 2018: 19 · 2017: 9
FWCI
5.17
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Review of Clinical Immunology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Regeneron Pharmaceuticals, Sanofi Pharmaceuticals and Genzyme
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
Keywords
IL-4/IL-13 pathway, type 2 inflammation, atopic diseases, atopic dermatitis, asthma, dupilumab, immunoglobulin E, allergic comorbidities
MeSH terms
Allergens, Asthma, Chronic Disease, Dermatitis, Atopic, Humans, Nasal Polyps, Sinusitis, Signal Transduction, Interleukin-4, Th2 Cells, Interleukin-13, Molecular Targeted Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Commonality of the IL-4/IL-13 pathway in atopic diseases. https://app.cochat.ai/papers/10.1080/1744666x.2017.1298443
The paper
Gandhi, N. A., Pirozzi, G., & Graham, N. M. H. (2017). Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Review of Clinical Immunology. https://doi.org/10.1080/1744666x.2017.1298443

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.